VSTM has been the subject of a number of other research reports. Roth Capital cut their target price on shares of Verastem from $14.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, May 14th. B. Riley reaffirmed a “buy” rating on shares of Verastem in a research report on Thursday, May 9th. Cantor Fitzgerald started coverage on shares of Verastem in a research report on Wednesday, April 3rd. They set an “overweight” rating and a $5.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of Verastem in a research report on Friday, May 10th. Finally, Zacks Investment Research raised shares of Verastem from a “sell” rating to a “hold” rating in a research report on Saturday, July 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $6.46.
Shares of NASDAQ VSTM traded up $0.09 during mid-day trading on Thursday, reaching $1.59. 1,980,156 shares of the company were exchanged, compared to its average volume of 2,413,359. The firm’s 50-day moving average is $1.49. The company has a debt-to-equity ratio of 1.42, a current ratio of 7.57 and a quick ratio of 7.56. The company has a market capitalization of $117.46 million, a PE ratio of -1.16 and a beta of 2.98. Verastem has a twelve month low of $1.16 and a twelve month high of $10.35.
Large investors have recently added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. bought a new position in Verastem during the first quarter worth about $30,000. Principal Financial Group Inc. bought a new position in Verastem in the 4th quarter valued at about $35,000. Amalgamated Bank bought a new position in Verastem in the 4th quarter valued at about $35,000. Commonwealth Equity Services LLC increased its holdings in Verastem by 43.2% in the 2nd quarter. Commonwealth Equity Services LLC now owns 26,697 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 8,054 shares during the period. Finally, BNP Paribas Arbitrage SA bought a new position in Verastem in the 1st quarter valued at about $42,000. 43.80% of the stock is currently owned by institutional investors and hedge funds.
Verastem Company Profile
Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.